Is Oscar Health, Inc. (NYSE:OSCR) a buy in 2026?
Hold. Oscar Health, Inc. is a wait-and-watch at today's price, not a fresh buy.
Individual ACA market darling with real profitability, but the entire thesis lives or dies on subsidies Washington is actively renegotiating.
Where OSCR is headed
By late 2027, Oscar Health looks like the winner nobody wanted to bet on in 2023. Revenue running at $16B+, membership past 2.5 million, and a technology stack (+Oscar) that finally has external customers paying real money rather than acting as a shop window. The company has done what UnitedHealth, Humana, and Centene couldn't: built a health insurer natively on modern software, priced individual ACA plans with actuarial discipline, and turned a category most incumbents treated as a loss leader into a 3-4% operating margin business. That is the bull mosaic if the politics cooperate.
Read the full Compass Direction on OSCR
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $29.45).
See the full OSCR analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Oscar Health, Inc. (NYSE:OSCR) a buy in 2026?
Hold. Oscar Health, Inc. is a wait-and-watch at today's price, not a fresh buy. Individual ACA market darling with real profitability, but the entire thesis lives or dies on subsidies Washington is actively renegotiating.
What is OSCR's Compass Score?
Oscar Health, Inc. scores 83/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for OSCR?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the OSCR page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.